by Jon Fleetwood,

The order was six times existing demand and equal to nearly 28 years of later annual bait sales, while DEFUSE-linked spray technology identified applications for “animals/humans.”

USDA-APHIS procurement memorandum dated March 6, 2018, specifying 6 million doses of experimental recombinant raccoonpox vaccine (RCN-F1-V307), valued at $1.3 million, for manufacture into plague-vaccine bait for prairie dogs at the USDA Pocatello Supply Depot in Idaho. The document predates the April contract award and was prepared the same month Project DEFUSE was submitted to DARPA.

According to a March 2018 U.S. Department of Agriculture Animal and Plant Health Inspection Service (USDA-APHIS) contract award to Colorado Serum Company, the federal government contracted for an estimated 6 million doses of recombinant raccoonpox plague vaccine, using the same vaccine-carrier platform Project DEFUSE proposed that month for spraying vaccine material onto bats.

The plague-vaccine order was six times the doses USDA said it needed for existing customers and equivalent to nearly 28 years of the depot’s subsequently reported annual vaccine-bait sales.

Meanwhile, DEFUSE’s proposed delivery partner, PARC, described aerosol technology for biological applications involving “animals/humans.”

DEFUSE is the project submitted the year before the COVID-19 pandemic to the Defense Advanced Research Projects Agency (DARPA) that characterized a pandemic response to a future SARS-CoV-2-like outbreak.

  • Why was the government contracting for millions of doses of a plague-vaccine platform while developing automated biological spraying?
  • What would be sprayed, and what informed consent protections would exist for potentially exposed people?

You can contact USDA here.

March 6, 2018 USDA-APHIS procurement justification identifies Colorado Serum Company as the proposed supplier of 6 million doses of experimental recombinant raccoonpox vaccine (RCN-F1-V307) for prairie-dog plague vaccination. The $1.3 million procurement was being prepared the same month Project DEFUSE proposed using the USGS raccoonpox platform for bat-vaccine delivery.
March 6, 2018 USDA-APHIS procurement justification, page 2: The agency identifies USGS and Colorado Serum Company as the only licensed manufacturers of the experimental raccoonpox plague vaccine, confirms USGS granted Colorado Serum exclusive selling rights, and states that Pocatello needed 1 million doses for existing orders—one-sixth of the 6 million doses specified in the proposed $1.3 million contract.

Ja Rcn Vaccine
238KB ∙ PDF file

Download

 


Six Million Doses—28 Years of Bait Sales

USDA’s Animal and Plant Health Inspection Service (APHIS) awarded Colorado Serum Company a roughly $1.3 million contract for an estimated 6 million doses of experimental recombinant raccoonpox vaccine, RCN-F1-V307.

The destination was USDA’s Pocatello Supply Depot in Idaho, where the vaccine would be mixed into wildlife bait.

Each vial held 4,000 doses.

The entire contracted quantity amounted to approximately 1,500 bottles, or 40 gallons.

The government’s justification said the depot needed 1 million doses to fill orders already received from federal, state, and tribal agencies.

Yet USDA contracted for six times that amount.

In fiscal 2019, the depot sold 216,000 finished plague-vaccine baits.

At that rate, 6 million doses represented nearly 28 years of sales.

March 6, 2018 USDA-APHIS procurement justification, Section 6: The government acknowledged needing just 1 million raccoonpox plague-vaccine doses to fulfill existing federal, state, and tribal orders, while proposing a 6-million-dose contract—six times the documented immediate demand. The same memorandum identifies USGS and Colorado Serum as the only licensed manufacturers and confirms USGS granted Colorado Serum exclusive selling rights.

The comparison measures the contract’s size, not how much inventory was actually delivered or stored.

A second delivery order worth $180,000 followed in April 2018.

  • Why did USDA contract for so much more vaccine than its documented immediate demand?

DEFUSE Named the Same Carrier—and a Sprayer for ‘Animals/Humans’

That same March, EcoHealth Alliance submitted Project DEFUSE to the Defense Advanced Research Projects Agency (DARPA).

The proposal named raccoonpox as a carrier for delivering vaccine material to bats, using sticky gel that bats would swallow while grooming.

It also proposed automated spraying technology developed with PARC.

The delivery team included Tonie Rocke of the U.S. Geological Survey (USGS), whose laboratory developed the raccoonpox vaccine platform already being manufactured for USDA.

DEFUSE-linked PARC material described large-area aerosol delivery of bioactive formulations and identified potential applications involving “animals/humans.”

In other words, the technology was not described exclusively for wildlife.

  • Why was a delivery system with stated human applications being developed alongside a federally supported wildlife-vaccine platform?

USDA Advanced Outdoor Spraying Despite Incomplete Human-Safety Evaluation

In July 2019, USDA-APHIS published environmental assessment APHIS-2019-0043-0003, addressing field testing of a recombinant raccoonpox bat vaccine called RCN-CAL/SP.

The proposed method involved vaccine-laden glycerin jelly applied by hand or spray, including directly onto bats or bat houses.

The assessment acknowledged that human safety had not been fully evaluated, while describing protective equipment for workers and assessing the risk as low.

The vaccine was intended to be swallowed by bats during grooming.

The spray technology was also receiving financial support.

In 2018, the National Fish and Wildlife Foundation supported a USGS-PARC bat-vaccine delivery project totaling approximately $829,466, including matching funds.

On May 13, 2020, USGS issued PARC a $198,940 purchase order, 140G0220P0134, to “DEVELOP&TEST SPRAY DEVICES.”

USGS subsequently reported treating more than 7,000 bats across seven states.

  • What exactly was applied at those sites, what environmental exposure testing occurred, and how were people protected from involuntary exposure?

Bottom Line

The government contracted for 6 million doses of the DEFUSE-linked raccoonpox platform in March 2018, six times documented immediate demand and equivalent to nearly 28 years of subsequently reported annual bait sales.

That same month, DEFUSE proposed using the platform for bat vaccination with automated spraying technology whose described applications included “animals/humans.”

By 2019, USDA was evaluating outdoor spraying of a related raccoonpox bat vaccine despite incomplete human-safety evaluation. During COVID, USGS funded additional spray-device development.

The plague-vaccine formulation ordered in 2018, the fungal-antigen bat vaccine evaluated in 2019, and the coronavirus-spike formulation proposed in DEFUSE were different products built around the same carrier platform.

The public deserves answers about the extraordinary procurement scale, the coordination of these programs, the substances actually sprayed, and the informed consent of people potentially exposed to federally supported biological releases.

 

Source: https://jonfleetwood.substack.com

Your Tax Free Donations Are Appreciated and Help Fund our Volunteer Website

Disclaimer: We at Prepare for Change (PFC) bring you information that is not offered by the mainstream news, and therefore may seem controversial. The opinions, views, statements, and/or information we present are not necessarily promoted, endorsed, espoused, or agreed to by Prepare for Change, its leadership Council, members, those who work with PFC, or those who read its content. However, they are hopefully provocative. Please use discernment! Use logical thinking, your own intuition and your own connection with Source, Spirit and Natural Laws to help you determine what is true and what is not. By sharing information and seeding dialogue, it is our goal to raise consciousness and awareness of higher truths to free us from enslavement of the matrix in this material realm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here